Collegium Pharmaceutical reported second quarter 2026 results with total net product revenues of $199.9 million, up 6% year-over-year, and non-GAAP adjusted EBITDA of $113.8 million, up 8%. Jornay PM net revenue grew 41% to $46.1 million, while Azstarys contributed $12.9 million following its May acquisition. The company updated full-year guidance to $825 million to $855 million in total product revenues and $445 million to $470 million in adjusted EBITDA, reflecting lower-than-expected NUCYNTA franchise revenue due to authorized generic pricing. Collegium also increased its Azstarys revenue outlook to $65 million to $75 million and maintained Jornay PM guidance of $190 million to $200 million.
Collegium Pharmaceutical IncQ2 earnings beat and raised guidance, though NUCYNTA weakness noted.
